Verseau Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $50M

  • Investors
  • 8

Verseau Therapeutics General Information

Description

Developer of macrophage checkpoint modulators designed to benefit patients with cancer. The company's technology utilizes lipid nanoparticles to identify novel targets and develop therapies that shift macrophages between immune activators and silencers, enabling physicians to provide patients with immunotherapies that induce a coordinated immune response to fight tumors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2000 Commonwealth Avenue
  • Suite 110
  • Auburndale, MA 02466
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Vertical(s)
Corporate Office
  • 2000 Commonwealth Avenue
  • Suite 110
  • Auburndale, MA 02466
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Verseau Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 21-Oct-2019 $50M Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 12-Feb-2019 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 30-Oct-2017 $4.3M $4.3M Completed Pre-Clinical Trials
To view Verseau Therapeutics’s complete valuation and funding history, request access »

Verseau Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Verseau Therapeutics’s complete cap table history, request access »

Verseau Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of macrophage checkpoint modulators designed to benefit patients with cancer. The company's technology utilize
Drug Discovery
Auburndale, MA
16 As of 2021

Vienna, Austria
 

Pittsburgh, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Verseau Therapeutics Competitors (21)

One of Verseau Therapeutics’s 21 competitors is APEIRON Biologics, a Formerly VC-backed company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
APEIRON Biologics Formerly VC-backed Vienna, Austria
Noveome Biotherapeutics Venture Capital-Backed Pittsburgh, PA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 21 competitors. Get the full list »

Verseau Therapeutics Patents

Verseau Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021281356-A1 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof Pending 29-May-2020
CA-3182814-A1 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof Pending 29-May-2020
EP-4157886-A1 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof Pending 29-May-2020
EP-4157886-A4 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof Pending 29-May-2020
US-12742011-B2 Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof Active 29-May-2020 C07K16/2827
To view Verseau Therapeutics’s complete patent history, request access »

Verseau Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verseau Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alexandria Venture Investments Venture Capital Minority
InHarv Partners Venture Capital Minority
3Sbio Corporation Minority
20/20 HealthCare Partners Family Office Minority
Alexandria Real Estate Equities Real Estate Minority
You’re viewing 5 of 8 investors. Get the full list »

Verseau Therapeutics FAQs

  • When was Verseau Therapeutics founded?

    Verseau Therapeutics was founded in 2017.

  • Where is Verseau Therapeutics headquartered?

    Verseau Therapeutics is headquartered in Auburndale, MA.

  • What is the size of Verseau Therapeutics?

    Verseau Therapeutics has 16 total employees.

  • What industry is Verseau Therapeutics in?

    Verseau Therapeutics’s primary industry is Drug Discovery.

  • Is Verseau Therapeutics a private or public company?

    Verseau Therapeutics is a Private company.

  • What is Verseau Therapeutics’s current revenue?

    The current revenue for Verseau Therapeutics is .

  • How much funding has Verseau Therapeutics raised over time?

    Verseau Therapeutics has raised $69.3M.

  • Who are Verseau Therapeutics’s investors?

    Alexandria Venture Investments, InHarv Partners, 3Sbio, 20/20 HealthCare Partners, and Alexandria Real Estate Equities are 5 of 8 investors who have invested in Verseau Therapeutics.

  • Who are Verseau Therapeutics’s competitors?

    APEIRON Biologics, Noveome Biotherapeutics, Adaptimmune Therapeutics, Carisma Therapeutics, and Inovio Pharmaceuticals are some of the 21 competitors of Verseau Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process